New Zealand markets closed

Johnson & Johnson (JNJ)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
163.72+0.32 (+0.20%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close163.40
Open163.06
Bid0.00 x 800
Ask0.00 x 800
Day's range162.96 - 164.06
52-week range133.65 - 179.92
Volume4,304,467
Avg. volume5,852,117
Market cap430.99B
Beta (5Y monthly)0.72
PE ratio (TTM)24.47
EPS (TTM)6.69
Earnings date19 Oct 2021
Forward dividend & yield4.24 (2.59%)
Ex-dividend date23 Aug 2021
1y target est188.29
  • Motley Fool

    Can AstraZeneca's COVID Antibody Therapy Win Against Regeneron and Eli Lilly?

    AstraZeneca (NASDAQ: AZN) awaits U.S. Emergency Use Authorization for its COVID-19 antibody therapy as a prophylaxis. In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss how effective AstraZeneca might be in competing against antibody therapies marketed by COVID-19 antibody therapies already on the market.

  • Motley Fool

    2 Upcoming FDA Approval Decisions That Investors Should Really Watch

    In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss two upcoming U.S. Food and Drug Administration (FDA) approval decisions that investors should keep an eye on. Keith Speights: Brian, on another note, the FDA is set to make several important approval decisions in the fourth quarter. Brian Orelli: Biomarin (NASDAQ: BMRN) has one coming up on Nov. 20.

  • Bloomberg

    J&J Loses a Round in Bankruptcy Spat Over Baby Powder Suits

    (Bloomberg) -- Johnson & Johnson can’t immediately halt lawsuits claiming the company’s talc baby powder hurt tens of thousands of women, a federal judge ruled.Most Read from BloombergCities' Answer to Sprawl? Go Wild.Why Americans and Britons Are Rushing to Buy Idyllic Homes in ItalyHamburg Is at the Heart of Germany’s Growing Dilemma Over ChinaOne of California’s Wealthiest Counties Could Run Out of Water Next SummerThe Top Money Maker at Deutsche Bank Reaps Billions From SingaporeU.S. Bankrup